Clinical Trial Update: Efficacy, Safety, Tolerability, and Biomarkers of Ibudilast (MN-166) in Patients Hospitalized With COVID-19 at Risk for ARDS [Phase 2]

View source ↗

Summary

Phase 2 trial assessing ibudilast (MN-166) in hospitalized COVID-19 patients at risk for ARDS reports on efficacy, safety, tolerability, and biomarker data.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumonia
• Respiratory Distress Syndrome

Drugs mentioned

• ibudilast (ibudilast)

Snippet

Sponsor: MediciNova | Conditions: Pneumonia, Viral | Phase 2 | Status: COMPLETED | Results posted: 2024-10-30